Precise radiation therapy for kidney tumors
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial uses a precise, high-dose radiation technique (called stereotactic body radiation therapy) that tracks and treats kidney tumors while you breathe. It aims to destroy tumors without surgery, potentially offering a less invasive option for people who cannot or prefer not to have an operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a kidney tumor (either primary kidney cancer or cancer that has spread to the kidney).
- You must be 18 years or older.
- The tumor must be no larger than 10 cm (about 4 inches) across.
- You must be in reasonably good health (able to care for yourself and walk around, though you may need some help).
- You must not have had radiation therapy to the kidney area before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a precise type of radiation therapy for small, early-stage kidney tumors that cannot be surgically removed or are at high risk for surgery. It aims to offer an alternative treatment with fewer side effects.
This trial studies whether stereotactic (high-precision) radiation given in a few sessions can control rare cancers that have spread to a small number of sites. It aims to help by treating all known spots while keeping side effects manageable.
This trial tests a precise type of radiation called stereotactic body proton therapy for people with kidney cancer who cannot have surgery or other local treatments. It aims to see if this focused radiation can control the tumor with fewer side effects.
This trial tests whether targeted, high-precision radiation (stereotactic radiotherapy) can control a small number of growing kidney cancer metastases while you continue systemic treatment. It may help people who have “oligoprogressive” disease, where only 1–3 spots are getting worse.
This trial tests a focused, high-dose radiation treatment (SABR) for kidney tumors that are too risky to remove with surgery or where surgery was declined. It may help shrink the tumor while limiting damage to surrounding tissue.
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
Hear when a new Renal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.